Wong-Won Shin

Title: Wong-Won Shin and Antibody Innovation for Hepatitis B

Introduction

Wong-Won Shin is an inventor associated with The Green Cross Corporation in Gyeonggi-do, South Korea. His patent work addresses antibody-based approaches to preventing or treating infection caused by hepatitis B virus (HBV), including mutant strains.

Latest Patents

Shin is associated with 1 patent: “Antibody Composition for Prevention or Treatment of Mutant Hepatitis B Virus Infection.” The invention describes an antibody that binds to the HBV surface antigen, HBsAg, and neutralizes the virus. The patent reports that the antibody can bind wild-type HBV as well as mutant viruses, including viruses with the YMDD polymerase mutation and the G145R surface-antigen mutation. It also describes testing with patient-derived viruses and an in vivo chimpanzee model, reporting neutralizing activity against wild-type HBV in that model. The proposed application is prevention or treatment of infections caused by wild-type and mutant HBV.

Career Highlights

Shin’s listed patent reflects work on antibody technology intended to address viral variants that may evade existing approaches. The invention focuses on targeting a viral surface antigen while retaining activity against multiple HBV forms.

Collaborations

The patent lists Se-Ho Kim and Ki Hwan Chang as Shin’s coworkers. The work is associated with The Green Cross Corporation.

Conclusion

Wong-Won Shin’s patent contribution centers on an antibody designed to neutralize wild-type and mutant hepatitis B viruses, highlighting an approach to broadening protection against HBV variants.